| 2026-09-21 |
NeoImmuneTech |
NeoImmuneTech Announces Continued Progress in CD19 CAR-T Combination Trial…Safety Confirmed in First Dose Cohort Following Two Doses of NT-I7 neoimmunetech.com ↗ |
| 2026-08-27 |
NeoImmuneTech |
NeoImmuneTech Announces Initiating First Patient Dosing in NIT-128 Trial Combining NT-I7 with BCMA CAR-T neoimmunetech.com ↗ |
| 2026-03-18 |
NeoImmuneTech |
NeoImmuneTech Highlights Publication of NT-I7 Study in Genes & Diseases, Demonstrating TLS Formation and Tumor Microenvironment Remodeling neoimmunetech.com ↗ |
| 2025-12-17 |
NeoImmuneTech |
NeoImmuneTech Highlights Potential to Overcome CAR-T Limitations at ASH 2025 NT-I7 Combination Enhances Both CAR-T Expansion and Persistence neoimmunetech.com ↗ |
| 2025-11-25 |
NeoImmuneTech |
NeoImmuneTech Confirms NT-I7’s New Mechanism in Tumor Microenvironment Remodeling — Renewed Spotlight on Long-Term Potential in Combination Immunotherapy neoimmunetech.com ↗ |
| 2025-11-20 |
NeoImmuneTech |
NeoImmuneTech Announces FDA IND Clearance for NIT-128, a Combination Trial of NT-I7 with BCMA CAR-T Therapy in Multiple Myeloma neoimmunetech.com ↗ |
| 2025-11-04 |
NeoImmuneTech |
NeoImmuneTech announces two NT-I7-based combination studies with CAR-T therapy have been accepted for presentation at ASH 2025 neoimmunetech.com ↗ |
| 2025-10-31 |
NeoImmuneTech |
NeoImmuneTech Announces U.S. FDA IND Submission for Combination Trial of NT-I7 with BCMA CAR-T Therapy Led by Washington University of Medicine in St. Louis— Expanding Its CAR-T Combination Strategy neoimmunetech.com ↗ |
| 2025-08-12 |
NeoImmuneTech |
NeoImmuneTech Announces FDA IND Clearance by Investigator for Repeat-Dosing Trial of NT-I7 post CAR-T Therapy neoimmunetech.com ↗ |
| 2025-07-14 |
NeoImmuneTech |
NeoImmuneTech Announces FDA IND Submission by Investigator for Repeat-Dosing Trial of NT-I7 post CAR-T Therapy neoimmunetech.com ↗ |
| 2025-05-19 |
NeoImmuneTech |
NeoImmuneTech Announces Final Topline Results of Phase 1b Study Combining NT-I7 with CAR-T Therapy neoimmunetech.com ↗ |
| 2025-04-25 |
NeoImmuneTech |
NeoImmuneTech to Present Preclinical Data on NT-I7’ s Immune Recovery and Antitumor Synergy at AACR 2025 neoimmunetech.com ↗ |
| 2024-12-07 |
NeoImmuneTech |
New Results Presented at ASH 2024: NeoImmuneTech's NT-I7 Demonstrates Promising T cell Reconstitution Following Radiation Injury neoimmunetech.com ↗ |
| 2024-09-08 |
NeoImmuneTech |
NeoImmuneTech Presents Promising Interim Results of CAR-T Combination with its NT-I7 Asset at ESMO 2024 neoimmunetech.com ↗ |
| 2024-06-03 |
NeoImmuneTech |
EMA Grants Orphan Drug Designation to NeoImmuneTech’s NT-I7 for the Treatment of Acute Radiation Syndrome neoimmunetech.com ↗ |
| 2024-06-03 |
NeoImmuneTech |
NeoImmuneTech’s New Data at ASCO 2024 Highlights Enhanced Benefits of Combining NT-I7 with Checkpoint Inhibitors in Immuno-Oncology neoimmunetech.com ↗ |
| 2024-05-13 |
NeoImmuneTech |
Duke University Receives $6 Million contract from National Institutes of Health to Study NeoImmuneTech's NT-I7 in Treating Acute Radiation Syndrome neoimmunetech.com ↗ |
| 2024-04-17 |
NeoImmuneTech |
NeoImmuneTech’s NT-I7 in Combination with Chemotherapy Shows Efficacy in Colorectal Cancer at AACR Meeting neoimmunetech.com ↗ |
| 2024-03-12 |
Selecxine |
rhIL-7-hyFc and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that improves antitumor efficacy of checkpoint inhibitors selecxine.com ↗ |
| 2024-01-29 |
NeoImmuneTech |
FDA Grants Orphan Drug Designation (ODD) Status to NeoImmuneTech’s NT-I7 for Advanced Pancreatic Cancer Treatment neoimmunetech.com ↗ |
| 2024-01-28 |
NeoImmuneTech |
Phase II Study Expansion Investigating NeoimmuneTech’s NT-I7 in Head and Neck Cancer neoimmunetech.com ↗ |
| 2023-11-19 |
NeoImmuneTech |
FDA Grants Orphan Drug Designation to NeoImmuneTech’s NT-I7 for the Treatment of Acute Radiation Syndrome neoimmunetech.com ↗ |
| 2023-10-03 |
NeoImmuneTech |
NeoImmuneTech to Present New Advances on NT-I7 (efineptakin alfa) at 2023 SITC Annual Meeting neoimmunetech.com ↗ |
| 2023-02-06 |
NeoImmuneTech |
First Patient Dosed in Phase II Study of NeoImmuneTech’s NT-I7 plus Pembrolizumab in Recurrent Glioblastoma neoimmunetech.com ↗ |
| 2022-11-13 |
NeoImmuneTech |
New evidence of NeoImmuneTech’s NT-I7 clinical efficacy in combination with pembrolizumab in relapsed/refractory (r/r) gastrointestinal tumors neoimmunetech.com ↗ |
| 2022-11-03 |
NeoImmuneTech |
NeoImmuneTech to Present First Data on NT-I7 (efineptakin alfa) in Combination with CAR-T tisagenlecleucel, at 2022 ASH Annual Meeting neoimmunetech.com ↗ |
| 2022-10-05 |
NeoImmuneTech |
NeoImmuneTech to Present New Advances on NT-I7 (efineptakin alfa) at 2022 SITC Annual Meeting neoimmunetech.com ↗ |
| 2022-09-12 |
NeoImmuneTech |
NeoImmuneTech’s NT-I7 Creates a More Immunogenic Tumor Microenvironment when Associated with Pembrolizumab neoimmunetech.com ↗ |
| 2022-07-12 |
NeoImmuneTech |
FDA Grants Orphan Drug Designation (ODD) Status to NeoImmuneTech’s NT-I7 for the treatment of Glioblastoma Multiforme neoimmunetech.com ↗ |
| 2022-07-03 |
NeoImmuneTech |
Interest of Combining NeoImmuneTech’s Lead Asset NT-I7 (efineptakin alfa) with Pembrolizumab keeps Growing neoimmunetech.com ↗ |
| 2022-06-15 |
NeoImmuneTech |
A Study in Nature Communications Reports that NeoImmuneTech's NT-I7 Enhances CAR-T Cell Expansion, Persistence and Anti-tumor Activity neoimmunetech.com ↗ |
| 2022-06-06 |
NeoImmuneTech |
NeoImmuneTech’s Lead Asset NT-I7 (efineptakin alfa) Shows Preliminary Anticancer Activity in Combination with Check-Point Inhibitors neoimmunetech.com ↗ |
| 2022-05-10 |
NeoImmuneTech |
NeoImmuneTech Received U.S. FDA Clearance of IND Application for Phase II Study of NT-I7 and Pembrolizumab in Recurrent Glioblastoma neoimmunetech.com ↗ |
| 2022-04-27 |
NeoImmuneTech |
NeoImmuneTech to Show Significant Advances on NT-I7 (efineptakin alfa) at 2022 ASCO Annual Meeting neoimmunetech.com ↗ |
| 2022-04-13 |
NeoImmuneTech |
NeoImmuneTech Demonstrates NT-I7’s Broad Combination Potential with Immune Checkpoint Inhibitors and Immunocytokine at AACR 2022 neoimmunetech.com ↗ |
| 2022-02-06 |
NeoImmuneTech |
NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) with PD-L1 checkpoint inhibitor in High-Risk Skin Cancers neoimmunetech.com ↗ |
| 2022-01-23 |
NeoImmuneTech |
Preclinical Data on NT-I7 Published in Clinical Cancer Research neoimmunetech.com ↗ |
| 2021-11-07 |
NeoImmuneTech |
NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) in combination with PD-L1 checkpoint inhibitor in Frontline Locally Advanced or Metastatic Non-Small Cell Lung Cancer neoimmunetech.com ↗ |
| 2021-10-12 |
NeoImmuneTech |
NeoImmuneTech Announces First Patient Dosed in Phase 1b Study of NT-I7 (efineptakin alfa) and Kymriah® (tisagenlecleucel) in Relapsed/Refractory Large B-Cell Lymphoma neoimmunetech.com ↗ |
| 2021-07-25 |
NeoImmuneTech |
NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1 Study of NT-I7 (efineptakin alfa) for the Treatment of Kaposi Sarcoma in Patients With or Without HIV Infection neoimmunetech.com ↗ |
| 2021-06-07 |
NeoImmuneTech |
NeoImmuneTech Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab) neoimmunetech.com ↗ |
| 2021-05-24 |
NeoImmuneTech |
NeoImmuneTech Announces First Patient Dosed in the Pilot Study of NT-I7 (efineptakin alfa) in Progressive Multifocal Leukoencephalopathy neoimmunetech.com ↗ |
| 2021-03-29 |
NeoImmuneTech |
NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) in Patients with High Grade Glioma neoimmunetech.com ↗ |
| 2021-03-22 |
NeoImmuneTech |
NeoImmuneTech Announces First Patient Dosed in Phase 2a Portion of Basket Study Evaluating NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in Relapsed/Refractory Advanced Solid Tumors neoimmunetech.com ↗ |
| 2021-02-22 |
NeoImmuneTech |
NeoImmuneTech Receives U.S. FDA IND Clearance for Pilot Study of NT-I7 (efineptakin alfa) in Progressive Multifocal Leukoencephalopathy neoimmunetech.com ↗ |
| 2021-02-15 |
NeoImmuneTech |
NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab) neoimmunetech.com ↗ |
| 2020-11-29 |
NeoImmuneTech |
NeoImmuneTech Announces First Patient Dosed in Phase 1 Study of NT-I7 (efineptakin alfa) in Adults with Mild COVID-19 neoimmunetech.com ↗ |
| 2020-11-15 |
NeoImmuneTech |
NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 2 Study of NT-I7 (efineptakin alfa) in combination with PD-L1 checkpoint inhibitor in First-line Non-small Cell Lung Cancer neoimmunetech.com ↗ |
| 2020-11-09 |
NeoImmuneTech |
Genexine and NeoImmuneTech Announce Data Release for their Phase 1b/2 Study of GX-I7/NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in patients with Triple-negative Breast Cancer neoimmunetech.com ↗ |
| 2020-10-20 |
NeoImmuneTech |
NeoImmuneTech Announces a Second Clinical Collaboration with Roche to Evaluate NT-I7 (efineptakin alfa) in Combination with PD-L1 checkpoint inhibitor in First-line Non-small Cell Lung Cancer neoimmunetech.com ↗ |
| 2020-08-23 |
NeoImmuneTech |
NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1b Study of NT-I7 (efineptakin alfa) and Kymriah® (tisagenlecleucel) in Relapsed/Refractory Large B-Cell Lymphoma neoimmunetech.com ↗ |
| 2020-07-26 |
NeoImmuneTech |
NeoImmuneTech Announces Receipt of IND Clearance to Conduct Window-of-Opportunity Trial of NT-I7 (efineptakin alfa) in Patients with Locally Recurrent Squamous Cell Carcinoma of Head and Neck neoimmunetech.com ↗ |
| 2020-07-26 |
NeoImmuneTech |
NeoImmuneTech Announces FDA Approval to Proceed with Second Study of NT-I7 (efineptakin alfa) in Adult COVID-19 Patients neoimmunetech.com ↗ |
| 2020-07-19 |
NeoImmuneTech |
NeoImmuneTech Receives U.S. FDA Clearance of IND Application for Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab) neoimmunetech.com ↗ |
| 2020-07-14 |
NeoImmuneTech |
NeoImmuneTech Announces Clearance for Investigational New Drug Application of NT-I7 (efineptakin alfa) in Adults with Mild COVID-19 neoimmunetech.com ↗ |
| 2020-06-24 |
NeoImmuneTech |
NeoImmuneTech Announces First Patient Dosed in Phase 1b/2a Study of NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in Patients with Relapsed/Refractory Advanced Solid Tumors neoimmunetech.com ↗ |
| 2020-06-14 |
NeoImmuneTech |
NeoImmuneTech Receives FDA Orphan Drug Designation for NT-I7 (efineptakin alfa) for the Treatment of Progressive Multifocal Leukoencephalopathy neoimmunetech.com ↗ |
| 2020-04-08 |
NeoImmuneTech |
NeoImmuneTech Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate NT-I7 (Hyleukin-7™) in Combination with Nivolumab neoimmunetech.com ↗ |
| 2020-01-27 |
NeoImmuneTech |
NeoImmuneTech Received U.S. FDA Clearance of IND Application for Phase 1b/2a Study of Hyleukin-7™ (NT-I7) and KEYTRUDA® (Pembrolizumab) in Relapsed/Refractory Advanced Solid Tumors neoimmunetech.com ↗ |
| 2019-12-10 |
NeoImmuneTech |
NeoImmuneTech Announces Clinical Collaboration to Evaluate Hyleukin-7™ (NT-I7) in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors neoimmunetech.com ↗ |
|